Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care

Exclusion Criteria

• •Histopathology is a neuroendocrine or small cell carcinoma
• •History of brain metastasis or signs of brain metastasis
• •Clinical diagnosis of hepatitis C or hepatitis B
• •Clinical diagnosis of human immunodeficiency virus (HIV)
• •History of HIV infection
• •Patients with heart failure, coronary artery disease(CAD) or Myocardial infarction in 6 month prior to screening. (LVEF is lower than 50% in screening visit)
• •Administered the drug for other clinical trials within 4weeks before participate in this trial
• •Administered any vaccines within 4weeks before participate in this trial (4 weeks for live vaccine, 2 weeks for other inactivated vaccine)
• •Administered the granulocytes concentrates within 3 months before the screening visit
• •Received chemotherapy or radiation therapy within 2 weeks before the 1st administration of investigational drug(BVAC-B)
• •Received following formulation within 1 months before the screening visit : Chronic steroids(more than 5 days), immunosuppressant or immunomodulatory agents. G-CSF
• •Patients who have participated in the clinical trial of a immunotherapeutic vaccine within 1 year or immunotherapy within 3 months before the screening visit
• •Patients who is pregnant or breast-feeding
• •Patients who researchers has determined that participation in the clinical trial is inappropriate
• •Suspected to have other progressive cancer or malignant tumor needs treatment in 3 years. Completely treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, thyroid carcinoma, cervical intraepithelial neoplasia are not included